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Rationale: Previously, we have been able to outpace bacterial mutation by replacing
increasingly ineffective antibiotics with new agents. However, with the discovery of new
antibiotics diminishing, optimising the administration of existing broad-spectrum antibiotics
such as co-amoxiclav has become a necessity.
Methods: A stability indicating HPLC method was developed and validated in compliance
with International Council for Harmonisation (ICH) guidelines. Stability of co-amoxiclav at
clinical concentration was evaluated at three temperatures (4°C, ambient (23–25°C) and 37°C)
in three diluents (water for injection (WFI), 0.9% w/v NaCl and Ringer’s solution). To
establish whether there were signiﬁcant differences at the level of both diluent and tempera-
ture, results were analysed using analysis of covariance (ANCOVA) to assess differences
between the attained slopes of regression.
Results: Data obtained indicated co-amoxiclav stability superior to that previously proposed
making it suitable for extended infusion therapy. The degradation of amoxicillin appeared to
follow a linear trend, with the rate of degradation elevated at higher temperatures, demon-
strated by the magnitude of the regression slopes in these conditions. Analysis of regression
slopes via ANCOVA demonstrated that diluent and temperature both signiﬁcantly affected
co-amoxiclav stability. Amoxicillin retained 90% of its initial concentration for 7.8 to 10 hrs
when stored at 4°C, 5.9 to 8.8 hrs at ambient and 3.5 to 4.5 hrs when incubated at 37°C.
Conclusion: Co-amoxiclav is suitable for administration via prolonged infusion. Findings
from this study aid in ameliorating current dosing regimens to optimise antibiotic efﬁcacy.
Other valuable applications conferred from these ﬁndings include the ability to pre-prepare
solutions for use in bolus administration, minimising preparation time and workload.
Keywords: prolonged infusion, co-amoxiclav and antibiotic resistance
Introduction
While the rate of antibiotic discovery has plummeted, the global burden of antimicro-
bial resistance (AMR) is on the rise and shows no signs of receding.1–3 Urgent action is
required to address this public health threat and halt the advent of a post-antibiotic era.
Recently, the World Health Organisation (WHO) identiﬁed signiﬁcant gaps in the
present status of surveillance and information on AMR and conﬁrmed that treatments
for commonly acquired infections are becoming less effective.4 Reduced susceptibility
to antibiotics, coupled with the lack of new agents has led to a renewed interest in
optimising currently available antimicrobials. One growing area for reducing the
development of AMR involves differential dosing regimens such as prolonged or
continuous infusions of time-dependent antibiotics.5–9 However, this may not be
possible for all antibiotics due to varying stability proﬁles.
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The European Pharmacopeia considers pharmaceuticals
stable providing they maintain 90% of their initial
concentration.10 Uncertainty regarding β-lactam antibiotic sta-
bility after reconstitution and dilution presents a challenge in
practice when assigning a shelf-life to injections that are pre-
prepared and stored in ready-to-administer containers.10 These
antibiotics display a time-dependent nature whereby maintain-
ing concentrations above the minimum inhibitory concentra-
tion (MIC) promotes maximal bactericidal activity.11
One such drug is amoxicillin–clavulanic acid (co-
amoxiclav), a combination β-lactam antibiotic/β-lactamase
inhibitor that exhibits broad-spectrum activity against
a wide variety of bacterial infections. Currently, parenteral
administration of co-amoxiclav is via bolus intermittent
infusion. A proposed dosing strategy for enhancing co-
amoxiclav’s efﬁcacy involves extending the time at which
concentrations are maintained above the MIC via continu-
ous/prolonged infusions.6 Prolonging infusion from 0.5 to 2
hrs has previously been associated with improvements in
time above the MIC (T>MIC).12
Literature indicates that the main constraints of co-
amoxiclav stability include infusion diluent and storage
temperature. Co-amoxiclav has been found to be less stable
at higher temperatures, with data suggesting that shelf-life
ranges between 1 and 5.5 hrs at room temperature in water
for injection (WFI) and up to 8 hrs at 4°C.13–16
To expand the breadth of current knowledge, this study
utilises the bench-to-bedside approach, where challenges
experienced in practice are addressed in the laboratory. Co-
amoxiclav stability is a crucial parameter that needs to be
determined to assess the feasibility of administration via
continuous/prolonged infusions. To address this, a high-
performance liquid chromatography (HPLC) stability indicat-
ing method (SIM) was developed and validated in compliance
with International Council for Harmonisation (ICH) guide-
lines. Quantitative analysis of co-amoxiclav stability was
then conducted in a range of temperatures and diluents to
determine their effect on degradation.
Materials and Methods
Materials
GSK pharmaceutical dosage form co-amoxiclav (1000mg/
200mg) infusion vials were provided by St George’s
Hospital, London, UK. Amoxicillin sodium, potassium cla-
vulanate and caffeine reference standards were purchased
from Sigma Aldrich, as were ammonium acetate and glacial
acetic acid. Water for injection (WFI), 0.9% sodium
chloride, and Ringer’s solution were purchased from The
Pharmacy, Kingston, UK. Methanol (HPLC grade) and
acetonitrile (HPLC grade) were purchased from VWR and
distilled water was generated in the laboratory at Kingston
University, London, UK.
Instrumentation
Quantitative analysis of amoxicillin–clavulanic acid was
carried out using an Agilent 1260 HPLC system with single
wavelength UV detection and Chemstation software.
HPLC-SIM Development & Validation
A SIM was developed and validated in accordance with
ICH guidelines. Parameters investigated included column,
mobile phase and internal standard selection. The method
was optimised through the selection of suitable ﬂowrate,
wavelength, injection volume and column temperature.
To determine the developed method’s speciﬁcity,
a forced degradation study was conducted. Co-amoxiclav
solutions were exposed to oxidative, hydrolytic, photolytic
and thermal stress. Stressed solutions were analysed to
assess the method’s ability to separate the parent com-
pounds from their degradation products.
Validation was conducted over the span of 3 days. The
analytical range was determined by running reference
standard amoxicillin–clavulanic acid at various concentra-
tions (0, 10, 20, 30, 40, 50, 60, 70, and 80ppm).
Quality control (QC) solutions equating to approxi-
mately 25%, 50% and 75% of the working range, ie
15ppm, 45ppm and 75ppm, were prepared prior to each
validation run to assess the accuracy. Precision was con-
sidered at three levels: repeatability, intermediate precision
and reproducibility through analysis of prepared QC solu-
tions. Three sets of each sample were prepared daily and
each sample was run in triplicate.
Method selectivity was demonstrated by analysing
“sample blanks” to observe any interferences at the deter-
mined amoxicillin and clavulanic acid retention times.
Robustness was examined by marginally varying the fol-
lowing parameters: ﬂow rate (±0.5mL/min), column tem-
perature (±5°C), wavelength (±10nm), injection volume
(±5μL) and mobile phase composition.
Quantitative HPLC Assay
In clinical settings, a 1.2g amoxicillin–clavulanic acid vial is
reconstituted with 20mL WFI and is diluted further with
50mL of diluent (1200mg/70mL = 17 143ppm). Nine phar-
maceutical formulation vials were reconstituted with 20mL
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WFI, further diluted with either 50mL of 0.9% sodium
chloride (n=3), Ringer’s solution (n=3) or WFI (n=3) and
stored at 4°C, ambient and 37°C in vials.
Standard practice involves dilution of co-amoxiclav
with sodium chloride solution. Other compatible diluents
including Ringer’s solution and WFI were trialled to
examine the inﬂuence of diluent on co-amoxiclav stability.
To evaluate preparation and storage feasibility, the stability
of co-amoxiclav solutions was assessed at 4°C. Ambient
and 37°C temperature conditions were considered in order
to mimic average and high temperatures experienced in
hospital wards due to seasonal variations.
To achieve a nominal concentration of 34.3ppm,
a dilution factor of 500x was used. Sampling was under-
taken every 2 hrs and the infusion solution was considered
stable while the percentage recovery of amoxicillin
remained above 90%.
Data and Statistical Analysis
Raw data obtained were corrected for drift and internal stan-
dard. Results are reported as the residual ratio of amoxicillin
concentration from three replicates. To determine whether
amoxicillin concentration decreased signiﬁcantly over time,
the slope of the linear regression line for each condition was
tested against the null hypothesis (H0 = no deviation from
zero) using a one-tailed t-test at the 99% level of signiﬁcance.
To establish whether there were signiﬁcant differences at the
level of both diluent and temperature, results were analysed
using analysis of covariance (ANCOVA) to assess differences
between the attained slopes of regression.
Results
HPLC-SIM Development and Validation
Amoxicillin, clavulanic acid and caffeine separation were
attained using conditions presented in Table 1. The method
demonstrated speciﬁcity with parent compounds separated
from their degradation products with sufﬁcient resolution.
A representative chromatogram is displayed in Figure 1.
The calibration curve (Figure 2) obtained demonstrated
good linearity over the concentration range of 0–80ppm.
The representative linear equation was y = 0.9951x +
0.00822 with correlation coefﬁcient (R2) of 0.9999. Good
intra-sample precision was achieved with %RSD ranging
between 0.07% and 1.66%. Intra-day precision ranged
between 0.65% and 5.63%.
Good inter-day precision was also obtained with %
RSD ranging between 1.16% and 1.80% (ICH acceptance
criteria: %RSD ≤ 5%). The percentage error ranged
between 0.07% and 8.78% and percentage recovery
between 91.22% and 105.23% (ICH acceptance criteria:
%Recovery: 80–120%), demonstrating good accuracy.
The method continued to perform optimally when
parameters were varied, exhibiting slight changes in reten-
tion time, peak areas and heights. LOD and LOQ were
calculated to be 1.57ppm and 4.76ppm, respectively.
Quantitative HPLC Assay
In general, amoxicillin–clavulanic acid solutions retained
more of the initial drug concentration at lower temperatures
compared with solutions stored at higher temperatures. The
inﬂuence of diluent on amoxicillin concentrations at 4°C,
ambient and 37°C over time is shown in Figure 3. The slopes
of the regression lines for each condition showed signiﬁcant
deviation from zero at the 99% level of conﬁdence, indicat-
ing amoxicillin exhibits degradation with time (Table 2).
Amoxicillin retained 90% of its initial concentration for
7.8 to 10 hrs when stored at 4°C, 5.9 to 8.8 hrs at ambient and
3.5 to 4.5 hrs when incubated at 37°C. Stability data for all
conditions are displayed in Table 2. Signiﬁcant differences
between regression slopes of temperature conditions for each
diluent were observed, as were differences between diluents
for each temperature condition (Table 3). Clavulanic acid
appeared to maintain concentrations within 90% of the initial
concentration for the entirety of the sampling duration in all
conditions analysed.
Discussion
The emergence of resistance threatens our capacity to treat
common infectious diseases as antibiotics progressively
Table 1 Displaying HPLC Parameters Investigated
Parameters Investigated Characteristic
Column Phenomenex Spherisorb 5 µm, 100
× 4.6 mm
Mobile Phase Ammonium Acetate Buffer (5mM)
pH 4: Acetonitrile (50:50 v/v)
Internal Standard Caffeine
Flow Rate 1.75mL/min
Injection Volume 10µL
Column Temperature 30°C
Wavelength 225nm
Run Time 2.5 mins
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become less effective.1–3 Optimising dosing regimens of
antibiotics has shown potential for controlling the spread
of resistance.5–9
The utilisation of the bench-to-bedside approach enables
outcomes to be translated directly from the laboratory to the
clinical setting, integrating these advancements into practice.
Sustaining serum concentrations above theMIC by employing
methods which exploit the time-dependent nature of co-
amoxiclav such as prolonged infusion could improve its clin-
ical effectiveness.17 Optimising co-amoxiclav efﬁcacy serves
not only to improve treatment strategies but also to minimise
the further development of antimicrobial resistance.
To our knowledge, this is the ﬁrst study of its kind to utilise
a multifactor analysis for determination of co-amoxiclav sta-
bility. By concomitantly examining drug stability at clinical
concentrations in multiple diluents across a range of tempera-
tures, a more comprehensive evaluation of multi-parameter
stability was attained. The consequent understanding of the
molecular stability of co-amoxiclav allows for a greater eva-
luation of its suitability for administration via prolonged infu-
sion, aiding in the development of novel treatment strategies.
Co-amoxiclav has not previously been considered for pro-
longed infusion; however, ﬁndings from this study demon-
strate its feasibility.
Results obtained conﬁrm that reconstitution diluent and
storage temperature signiﬁcantly inﬂuence co-amoxiclav sta-
bility. The degradation of amoxicillin appeared to follow
a linear trend, with the rate of degradation elevated at higher
temperatures as demonstrated by themagnitude of the regres-
sion slopes in these conditions. Storage at lower temperatures
correlated with increased shelf-life, which is concurrent with
previous studies on other β-lactam antibiotics6,18,19 (Table 2).
Dilution with Ringer’s solution demonstrated the least
stability, exhibiting signiﬁcant differences compared to sal-
ine andWFI when stored at both 4°C and ambient conditions
(Table 3). Greatest stability of amoxicillin was achieved in
WFI and saline solutions at 4°C, where shelf-lives of 9.6 and
10.0 hrs, respectively, were determined (Table 2).
Figure 2 Amoxicillin–clavulanic acid nine-point calibration (internal standard cor-
rected) displaying linearity over the range of 0–80ppm.
Figure 1 Chromatogram displaying clavulanic acid (tR: 1.117 mins), amoxicillin (tR: 1.565 mins) and caffeine (tR: 1.820 mins) separation.
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A 
B 
C 
Figure 3 Stability of amoxicillin over time at (A) 4°C, (B) ambient and (C) 37°C: mean % of intact molecule as a function of time and type of diluent. Error bars: ± standard
deviation. Dashed line: 90% of initial concentration.
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Data obtained indicated co-amoxiclav stability superior
to that previously proposed13–16 making it suitable for
extended infusion therapy. Prolonged co-amoxiclav infu-
sion would improve the effectiveness of therapy without
altering the dose or dosing schedule, giving no increase in
toxicity. Insight into this greater stability paves the way for
further investigation of differential dosing regimens and
optimisation of current treatment strategies, which have
the potential to improve and enhance clinical efﬁcacy.
Another valuable application conferred from these
ﬁndings includes the ability to pre-prepare solutions for
use in bolus administration, minimising preparation time
and workload. Furthermore, unused reconstituted solutions
are typically discarded after use; however, this study
demonstrates that these may be utilised for subsequent
administrations, reducing wastage and costs.
Future assays investigating the stability of co-
amoxiclav should consider analysis at a range of concen-
trations to account for patient populations with speciﬁc
dosing requirements, such as those on ﬂuid restriction
due to reduced renal clearance. Further investigations are
warranted to understand the stability of co-amoxiclav in
Table 2 Displaying the Linear Regression Equations for Each Condition Used to Calculate the Predicted Time at Which Residual Ratio
of Amoxicillin Falls Below 90%
Condition Deviation of Slope from Zero Linear Equation Predicted Stability (hrs)
4°C Saline Signiﬁcant p < 0.0001 y = −1.167x + 101.1 10.03
4°C WFI Signiﬁcant p < 0.0001 y = −1.261x + 102.1 9.60
4°C Ringer’s Solution Signiﬁcant p < 0.0001 y = −1.440x + 101.2 7.78
Ambient Saline Signiﬁcant p < 0.0001 y = −1.355x + 101.9 8.78
Ambient WFI Signiﬁcant p < 0.0001 y = −1.438x + 100.8 7.51
Ambient Ringer’s Solution Signiﬁcant p < 0.0001 y = −1.792x + 100.6 5.92
37°C Saline Signiﬁcant p = 0.0001 y = −2.560x + 99.35 3.65
37°C WFI Signiﬁcant p < 0.0001 y = −2.449x + 101.0 4.49
37°C Ringer’s Solution Signiﬁcant p < 0.0001 y = −3.299x + 101.8 3.58
Table 3 Results of ANCOVA Analyses Performed at the Level of Diluent and Temperature.
Diluent ANCOVA (All Temperature Conditions) ANCOVA (Individual Analyses)
Saline (4°C, Ambient, 37°C) Signiﬁcant p = 0.019 4°C vs Ambient: p = 0.875 (NS)
4°C vs 37°C: p = 0.007 (S)
Ambient vs 37°C: p = 0.009 (S)
WFI (4°C, Ambient, 37°C) Signiﬁcant p = 0.004 4°C vs Ambient: p = 0.048 (S)
4°C vs 37°C: p = 0.024 (S)
Ambient vs 37°C: p = 0.063 (S)
Ringer’s Solution (4°C, Ambient, 37°C) Signiﬁcant p = 0.026 4°C vs Ambient: p = 0.160 (S)
4°C vs 37°C: p = 0.047 (S)
Ambient vs 37°C: p = 0.184 (S)
Temperature ANCOVA (All Diluent Conditions) ANCOVA (Individual Analyses)
4°C (Saline, WFI, Ringer’s Solution) Signiﬁcant p = 0.135 Saline vs WFI: p = 0.629 (NS)
Saline vs Ringers: p = 0.07 (S)
Ringers vs WFI: p = 0.065 (S)
Ambient (Saline, WFI, Ringer’s Solution) Signiﬁcant p = 0.023 Saline vs WFI: p = 0.125 (S)
Saline vs Ringers: p = 0.07 (S)
Ringers vs WFI: p = 0.233 (S)
37°C (Saline, WFI, Ringer’s Solution) Not signiﬁcant p = 0.919 Saline vs WFI: p = 0.289 (NS)
Saline vs Ringers: p = 0.925 (NS)
Ringers vs WFI: p = 0.408 (NS)
Abbreviations: S, signiﬁcant; NS, not signiﬁcant at 75% conﬁdence level.
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various infusion devices such as elastomeric pumps and
intravenous infusion bags.
Conclusion
Resistance to common infections has previously been
mitigated by the discovery of novel antibiotics. However,
with the current scarcity of newly developed compounds,
this study focused on optimising the administration of
broad-spectrum co-amoxiclav by determining its shelf-
life in a range of temperatures and diluents. Results sug-
gest co-amoxiclav shelf-life is longer than previously
determined, rendering it suitable for administration via
prolonged infusion in terms of stability. Multifactor ana-
lysis indicated that co-amoxiclav stability was signiﬁcantly
inﬂuenced by diluent and storage temperature. Findings
from this study aid in ameliorating current dosing regi-
mens to optimise antibiotic efﬁcacy.
Disclosure
The authors report no conﬂicts of interest in this work.
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